BNP Paribas Financial Markets
STSA

BNP Paribas Financial Markets’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

BNP Paribas Financial Markets’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-59
Closed -$354 – 4854
2022
Q3 		$354 Buy
+59
New +$335 ﹤0.01% 4555

Other funds holding STSA

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

BNP Paribas Financial Markets's STSA Position: Q4 2022 in Review

BNP Paribas Financial Markets sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2022, closing a stake of 59 shares — an estimated $354 sold.

BNP Paribas Financial Markets first reported a position in STSA in Q3 2022 and held it in 1 quarter. The position peaked at $354 in Q3 2022. 33 funds tracked by Wall St. Rank hold STSA as of Q4 2022.

  • BNP Paribas Financial Markets reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 59 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $354.
  • BNP Paribas Financial Markets first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • BNP Paribas Financial Markets's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $354 in Q3 2022.
  • 33 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.